This poster, presented at the 16th International Pathogenic Neisseria Conference in the Netherlands, discusses a study that aimed to provide preliminary information regarding meningococcal carriage in West Africa and on the effect on carriage of MenAfriVac, a novel tetanus toxoid conjugate Neisseria meningitidis serogroup A vaccine. The authors concluded that study results revealed substantial serogroup hetherogenicity between countries. They also noted that serogroup A isolates were nearly absent, so no conclusion on the impact of MenAfrivac conjugate vaccine in these study populations could be drawn.

Author(s): Caugant DA, Tamboura B, Tapia M, et al.

Published: 2008

Resource types: Presentation

Diseases: Meningococcus

Topics: Disease burden and surveillance; Disease/vaccine specific information

Regions: Africa